A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.

Trial Profile

A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs Ixabepilone (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 17 Dec 2008 Data from a pooled analysis (CA163-046 and CA163-048) presented at San Antonio Breast Cancer Conference 2008.
    • 10 Dec 2008 Results of a pooled analysis (study 046 and 048) investigating outcomes in patients with triple negative disease were presented at the 31st Annual San Antonio Breast Cancer Symposium in Dec 2008.
    • 07 Sep 2008 Overall survival and updated results data have been reported at the 2008 American Society of Clinical Oncology Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top